<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061811</url>
  </required_header>
  <id_info>
    <org_study_id>7952_BO_S_2018</org_study_id>
    <secondary_id>KlinStrucMed program</secondary_id>
    <nct_id>NCT04061811</nct_id>
  </id_info>
  <brief_title>Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients</brief_title>
  <acronym>SONGBIRD</acronym>
  <official_title>Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>F-CRIN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: The aim of this study is to determine whether growth differentiation factor-15
      (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure
      (HF) in patients on dialysis.

      Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of
      NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers
      of distinct mechanisms that may contribute to HF pathophysiology in such cohorts.

      Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP
      activity in patients on chronic dialysis without and with HF, as diagnosed by clinical
      parameters and post-dialysis echocardiography. We use correlation, linear and logistic
      regression as well as receiver operating characteristic (ROC) analyses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HF diagnosis</measure>
    <time_frame>Baseline (at study entry (diagnostic biomarker study))</time_frame>
    <description>Diagnosis of HF</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">153</enrollment>
  <condition>Heart Failure</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>HF (heart failure)</arm_group_label>
    <description>Patients with end stage renal disease requiring dialysis with reduced or preserved ejection fraction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with end stage renal disease requiring dialysis without HF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic biomarker study</intervention_name>
    <description>Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>HF (heart failure)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, peritoneal dialysate.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        End stage renal disease (ESRD) patients on chronic dialysis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months

        Exclusion Criteria:

          -  previous switch of the type of renal replacement therapy from HD to PD or vice versa

          -  age &lt;18 years

          -  pregnancy

          -  plasma exchange or apheresis in the past 6 months

          -  unipolar pacemaker

          -  history of whole extremity amputation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Balzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inserm Umr S-942</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30175</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hannover Medical School</investigator_affiliation>
    <investigator_full_name>Michael Sören Balzer</investigator_full_name>
    <investigator_title>Postdoctoral fellow</investigator_title>
  </responsible_party>
  <keyword>congestive heart failure (HF)</keyword>
  <keyword>biomarker</keyword>
  <keyword>chronic kidney disease (CKD)</keyword>
  <keyword>hemodialysis (HD)</keyword>
  <keyword>peritoneal dialysis (PD)</keyword>
  <keyword>neprilysin (NEP)</keyword>
  <keyword>growth differentiation factor-15 (GDF15)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

